171 related articles for article (PubMed ID: 10999215)
21. AIDS 1997. Vaccines and immunology: overview.
Hu S; Norrby E
AIDS; 1997; 11 Suppl A():S85-6. PubMed ID: 9451971
[No Abstract] [Full Text] [Related]
22. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
23. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
[TBL] [Abstract][Full Text] [Related]
24. HIV vaccine development: perspective.
Bolognesi DP
Biotechnol Ther; 1991; 2(1-2):205-11. PubMed ID: 1845122
[No Abstract] [Full Text] [Related]
25. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
26. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
McFarland EJ; Borkowsky W; Fenton T; Wara D; McNamara J; Samson P; Kang M; Mofenson L; Cunningham C; Duliege AM; Sinangil F; Spector SA; Jimenez E; Bryson Y; Burchett S; Frenkel LM; Yogev R; Gigliotti F; Luzuriaga K; Livingston RA;
J Infect Dis; 2001 Nov; 184(10):1331-5. PubMed ID: 11679925
[TBL] [Abstract][Full Text] [Related]
27. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
28. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.
Yamamoto JK; Pu R; Sato E; Hohdatsu T
AIDS; 2007 Mar; 21(5):547-63. PubMed ID: 17314517
[No Abstract] [Full Text] [Related]
29. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
32. Current status of the development of an AIDS vaccine.
Lasky LA
Crit Rev Immunol; 1989; 9(3):153-72. PubMed ID: 2673294
[TBL] [Abstract][Full Text] [Related]
33. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
34. Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
Desrosiers R
J Int Assoc Physicians AIDS Care; 1998 Mar; 4(3):45-6. PubMed ID: 11365180
[TBL] [Abstract][Full Text] [Related]
35. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
37. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
38. Artificial antigens for HIV vaccine design.
Expert Rev Vaccines; 2007 Jun; 6(3):301. PubMed ID: 17542744
[No Abstract] [Full Text] [Related]
39. Prospects for a human immunodeficiency virus/AIDS vaccine.
Murphy FA; Folks TM; Lairmore MD
Dev Biol Stand; 1990; 72():3-15. PubMed ID: 1704324
[No Abstract] [Full Text] [Related]
40. Vaccine to prevent AIDS.
Tyring S
Res Initiat Treat Action; 1999 Jan; 5(1):9-10. PubMed ID: 11366234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
